1. Academic Validation
  2. Dysregulation of CD4+ and CD8+ resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitis

Dysregulation of CD4+ and CD8+ resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitis

  • J Immunother Cancer. 2024 Apr 19;12(4):e008628. doi: 10.1136/jitc-2023-008628.
Jun Yan He 1 Yang-Joon Kim 2 Elvira Mennillo 3 Iulia Rusu 3 Jared Bain 3 Arjun A Rao 4 Christopher Andersen 4 Karen Law 1 Hai Yang 1 Jessica Tsui 4 Alan Shen 4 Brittany Davidson 4 Divyashree Kushnoor 4 Yimin Shi 1 Frances Fan 1 Alexander Cheung 1 Li Zhang 1 Lawrence Fong 1 Alexis J Combes 3 4 5 6 Angela O Pisco 2 Michael G Kattah # 7 David Y Oh # 8
Affiliations

Affiliations

  • 1 Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
  • 2 Chan Zuckerberg Biohub, San Francisco, California, USA.
  • 3 Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • 4 CoLabs, University of California, San Francisco, San Francisco, California, USA.
  • 5 Department of Pathology, University of California, San Francisco, San Francisco, California, USA.
  • 6 ImmunoX Initiative, University of California, San Francisco, San Francisco, California, USA.
  • 7 Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA David.Oh@ucsf.edu michael.kattah@ucsf.edu.
  • 8 Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA David.Oh@ucsf.edu michael.kattah@ucsf.edu.
  • # Contributed equally.
Abstract

Background: Colitis caused by checkpoint inhibitors (CPI) is frequent and is treated with empiric Steroids, but CPI colitis mechanisms in steroid-experienced or refractory disease are unclear.

Methods: Using colon biopsies and blood from predominantly steroid-experienced CPI colitis patients, we performed multiplexed single-cell transcriptomics and proteomics to nominate contributing populations.

Results: CPI colitis biopsies showed enrichment of CD4+resident memory (RM) T cells in addition to CD8+ RM and cytotoxic CD8+ T cells. Matching T cell receptor (TCR) clonotypes suggested that both RMs are progenitors that yield cytotoxic effectors. Activated, CD38+ HLA-DR+ CD4+ RM and cytotoxic CD8+ T cells were enriched in steroid-experienced and a validation data set of steroid-naïve CPI colitis, underscoring their pathogenic potential across steroid exposure. Distinct from ulcerative colitis, CPI colitis exhibited perturbed stromal metabolism (NAD+, tryptophan) impacting epithelial survival and inflammation. Endothelial cells in CPI colitis after anti-TNF and anti-cytotoxic T-lymphocyte-associated antigen 4 (anti-CTLA-4) upregulated the Integrin α4β7 ligand molecular vascular addressin cell adhesion molecule 1 (MAdCAM-1), which may preferentially respond to vedolizumab (anti-α4β7).

Conclusions: These findings nominate CD4+ RM and MAdCAM-1+ endothelial cells for targeting in specific subsets of CPI colitis patients.

Keywords

Colitis; Immune Checkpoint Inhibitor; Immune related adverse event - irAE; Memory.

Figures
Products